

Robert Popovian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10267890/publications.pdf>

Version: 2024-02-01

10
papers

873
citations

1478280

6
h-index

1372474

10
g-index

10
all docs

10
docs citations

10
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	The cost of treating community-acquired pneumonia. <i>Clinical Therapeutics</i> , 1998, 20, 820-837.	1.1	488
2	Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. <i>Advances in Therapy</i> , 2016, 33, 2160-2172.	1.3	165
3	Treatment cost of acute exacerbations of chronic bronchitis. <i>Clinical Therapeutics</i> , 1999, 21, 576-591.	1.1	138
4	Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1047-1062.	1.7	34
5	Biosimilars: Practical Considerations for Pharmacists. <i>Annals of Pharmacotherapy</i> , 2017, 51, 590-602.	0.9	24
6	Sowing confusion in the field: the interchangeable use of biosimilar terminology. <i>Current Medical Research and Opinion</i> , 2019, 35, 619-621.	0.9	9
7	Nonsteroidal anti-inflammatory drugs: The need for assessment and education. <i>Home Care Provider</i> , 2001, 6, 100-105.	0.1	6
8	Accessibility of adult immunizations in pharmacies compared to physician offices in low-income communities. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 1644-1647.	0.7	4
9	Pharmaceutical Care Environment on the Health Care Expenditures of Medicare HMO Enrollees. <i>Journal of Managed Care Pharmacy</i> , 1999, 5, 414-419.	2.2	3
10	Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent. <i>Journal of Commercial Biotechnology</i> , 2021, 26, .	0.2	2